Chronology of some landmarks in the field of ALCL
• 1982: The recognition of the new pathological entity 'anaplastic large cell lymphoma (ALCL)' (which was first alternatively termed 'Ki-1 lymphoma') can be traced back to the production of a monoclonal antibody (McAb) against an antigen on the Hodgkin's disease (HD)-derived cell line L428. 1, 2 The McAb was designated Ki-1 and was initially thought to specifically detect Hodgkin/Reed-Sternberg (H-RS) cells but not cells from non-Hodgkin's lymphomas (NHL). The Ki-1 and other McAbs recognizing the same antigen were later assigned to the CD30 group. 3 • 1985: The Ki-1 antigen was found on tumor cells of 45 cases of diffuse large cell lymphoma (DLCL), most of which had originally been diagnosed as malignant histiocytosis or anaplastic carcinoma (because of their bizarre morphology). While lacking any monocyte-macrophage antigens, the cells expressed T cell-or B cell-associated antigens or were devoid of any T or B cell markers. 4 The term 'ALCL' was coined here.
• 1985/1986: Several cases of malignant histiocytosis carrying the (2;5)(p23;q35) chromosomal translocation were described. Malignant histiocytosis appeared to be characterized at the chromosomal level by changes in band 5q35. 5, 6 • 1986: Kadin et al 7 used the term 'Ki-1 lymphoma' in a report describing large cell lymphomas in children and adolescents with the initial diagnoses of malignant or regressing atypical histiocytosis. Thus, the Ki-1 lymphoma became defined as a clinicopathological entity.
• 1988: The new pathological entity was listed in the Updated Kiel Classification of Non-Hodgkin's Lymphomas as 'large cell anaplastic (Ki-1 Leukemia included among the morphological variants of 'diffuse large B cell lymphoma'.
• 1994: Cloning of the genes altered by the t(2;5) (cytogenetically detected in many ALCL cases) showed the fusion of the NPM gene on chromosome band 5q35 to the previously unidentified gene ALK on 2p23. 11, 12 This provided the means to apply polymerase chain reaction (PCR) technology for the diagnostic detection of the t(2;5).
• 1994: The production of the anti-p80 polyclonal antiserum detecting the fusion protein of the t(2;5) by Shiota et al 13 allowed for the immunohistochemical diagnosis of ALCL cases carrying the t(2;5).
• 1995: Orscheschek et al 14 found the t(2;5) in 11/13 patients with HD. This finding stirred a tremendous amount of controversy, but was ultimately not reproducible.
• 1997: Pulford et al 15 produced the McAb ALK1 against the NPM-ALK chimeric and normal ALK protein. The availability of ALK1 for immunostaining of routine biopsy material led to the definition of the 'ALK lymphoma/ALKoma' in 1998. [16] [17] [18] • 1999: The new WHO (World Health Organization) classification of lymphomas is similar to the REAL classification, 19 distinguishing three morphological variants of ALCL (common type, lympho-histiocytic variant, small cell variant) and assigning the borderline form of ALCL-Hodgkin's like to classical HD rather than to ALCL. 20, 21 • 1999/2000: Three fusion gene variants were cloned, ATIC-ALK, TFG-ALK and TPM3-ALK, showing that ALK can form chimeric genes with partners other than NPM.
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Incidence of ALCL
Incidence
ALCL is a relatively infrequent tumor. Four large studies have provided detailed data on the percentage of ALCL in adults among all types of NHL or among DLCL (Table 1) : about 2% a Number of ALCL cases per total number of lymphoma cases (NHL or DLCL). b Canada, France, Germany, Hong Kong, Switzerland, South Africa, UK, USA. ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; CD, cluster of differentiation; DLCL, diffuse large cell lymphoma; EBV, Epstein-Barr virus; FICTION, fluorescence immunophenotyping and interphase cytogenetics as a tool for investigation of neoplasms; FISH, fluorescence in situ hybridization; H-RS, Hodgkin-Reed-Sternberg (cell); HD, Hodgkin's disease; IHS, immunohistochemical staining; LCL, large cell lymphoma; LTK, leukocyte tyrosine kinase; LyP, lymphomatoid papulosis; McAb, monoclonal antibody; MDS, myelodysplastic syndromes; MLF, myelodysplasia/myeloid leukemia factor; n.g., not given; NHL, non-Hodgkin's lymphoma; NPM, nucleophosmin; PCR, polymerase chain reaction; PTCL, peripheral T cell lymphoma; RARA, retinoid acid receptor ␣; REAL, Revised European-American Classification of Lymphoid Neoplasms; RISH, RNA in situ hybridization; RT-PCR, reverse transcriptase-PCR; RTK, receptor tyrosine kinase; TFG, TRK-fused gene; TPM, non-muscular tropomyosin; TRK, tropomyosin receptor kinase.
of all adult NHL and about 4-8% of the adult DLCL. With regard to children, the incidence of ALCL among pediatric NHL is about 13% (range 10-16% in four studies) (Table 1) and 30-40% of all childhood LCL. 35, 36 Taking these ALCL incidence rates and cancer statistics review data for NHL into account, it can be estimated that about 1000 new ALCL cases occur per year in the USA and about 1200 new cases in the 15 countries of the European Union.
Diagnostic accuracy and reproducibility
A large expert panel study showed that histology alone is definitely insufficient to arrive at the correct diagnosis of ALCL. Inclusion of immunophenotyping data improved the diagnostic accuracy to 85% and the reproducibility/ concordance of the diagnosis among experts to at least 85%. 28, 33 As ALCL is by definition CD30 + , this marker would appear to be the most valuable in the diagnostic procedure. However, CD30 is not specific for ALCL and cannot be used as the sole criterion to define the entity, without morphology; for example, many cases of non-ALCL peripheral T cell lymphomas are CD30
+ (reviewed in Refs 37 and 38) . Hence there is a need to base the diagnosis of ALCL on a combination of histology, immunophenotype and clinical data. The distinction of CD30 + ALCL from CD30 + non-ALCL has remained controversial and for reviews on the CD30 antigen as a diagnostic tool and CD30
+ malignant lymphomas see Refs 39-41.
Distribution of immunophenotypes
The majority of tumors with the ALCL morphology express one or more T cell-associated antigens (T cell type), a large percentage express neither T nor B cell-associated antigens (so-called Null cell type), and some cases express B cell antigens. 10, 42 These latter CD30 + cases, which are histologically anaplastic and large cell but carry a B cell immunophenotype ('B cell ALCL'?) are now assigned to the entity DLCL B cell. 10 As can be expected, however, the literature is still confusing as some studies included 'B cell ALCL', whereas others excluded them (see also below under 'Controversies'). Many Null cell cases showed T cell receptor gene rearrangements and an expanded immunophenotyping panel might shift the balance even more towards a T cell origin. 43 Table 2 provides an overview on the distribution of the various immunotypes in ALCL as reported in the literature. These studies, including B cell cases, showed the following distribution: T cell 52% (range 28-88%), Null cell 29% (7-54%), B cell 17% (4-41%), hybrid 2% (2-20%); studies excluding B cell cases: T cell 77% (59-94%), Null cell 23% (6-42%). However, shifting definitions and differences in the interpretation of diagnostic criteria render attempts to determine the 'true' incidence of ALCL and its immunotypes largely futile.
Histopathology of ALCL
Morphological variants
ALCL have a distinctive histological appearance and the characteristic cytological appearance of the tumor cells in the context of the typical architectural features allows for the recognization of ALCL in the large majority of cases.
4,51,66,67 Subsequent observations have, however, noted a wide cytological Leukemia spectrum with quite diverse morphological variants. 68 Thus, the morphological spectrum of ALCL has been greatly expanded. According to these morphological features, ALCL can be subdivided into different groups 16 (Table 3) . The common/classical type is by far the most frequent form, Incidence rates were calculated from data published in 10 studies on a total of 598 ALCL patients. 17, 27, 30, 34, 47, 49, 50, 63, 76, 77 Indicated are the means of all cases combined and in parentheses the range of incidence rates between the various studies (not all studies included the same variants). b Detailed descriptions of the ALCL variants are found in the references indicated.
appearing in about 78% of cases of ALCL. Histological variations within the common type have also been variously described by investigators as pale vs basophilic and monomorphic vs pleomorphic. 52, 55 The less common variants include HD-like variant (6%), small cell predominant variant (6%), and lymphohistiocytic variant (4%) ( Table 3) . For reviews on the histology of ALCL and its morphological variants see Refs 43, 67, 68. 
Distinction from true histiocytic malignancies
It appears that many cases of ALCL were previously diagnosed as malignant histiocytic tumors, regressing atypical histiocytosis, metastatic carcinoma, melanoma, sarcoma, or lymphocyte-depleted HD. 10 In particular, the lymphohistiocytic variant of ALCL was widely considered to be a certain type of true histiocytic malignancy. 67 These malignant histiocytic tumors were thought to be derived from the mononuclear phagocyte system; the two most prominent malignancies were malignant histiocytosis and true histiocytic lymphoma. See Refs 78-80 for detailed discussions of normal histiocytes and neoplastic histiocytosis. The clinicopathological studies that defined these entities were performed prior to the advent of modern immunophenotyping, genotyping and molecular biology currently being used in diagnostic pathology. 81 Upon re-analysis of cases previously diagnosed as malignant histiocytosis, it became clear that the majority of these cases required reclassification as LCL or ALCL and that true histiocytic neoplasms are extremely rare. 82, 83 In a large study of 925 NHL, only four cases (0.4%) appeared, on the basis of immunophenotyping and genotyping, to be of true histiocytic origin. 84 Following documention of T cell immunoprofiles and T cell receptor rearrangements, the histiocytic origin of regressing atypical histiocytosis was considered questionable as well. 85 
Distinction from Hodgkin's disease
The differential diagnosis of HD-like variant ALCL from HD can be difficult as the border between the histopathological features of ALCL and HD is not always distinct. 43, 68, 86 The notion of a continuous spectrum of tumor types intermediate between HD and ALCL has been proposed. 69, 87 Markers and characteristics that provide guidance in diagnosing and distinguishing these borderline cases have been summarized elsewhere. 42, 43, 67, 68 It appears to be not entirely clear whether HD-like ALCL is a specific subentity or constitutes a heterogenous group of lymphomas; hence the current consideration of including these cases in the HD category proper ('ALCLlike HD'). 16 The distinction of HD from ALCL has been been discussed in greater detail in Refs 88-92.
Distinction from lymphomatoid papulosis
The distinction of ALCL in the skin from lymphomatoid papulosis (LyP) may represent a difficult differential diagnosis. 68 Primary cutaneous ALCL and LyP have overlapping histological and clinical features and are considered to represent a continuous spectrum. 93 Three histological types of LyP have been described with various degrees to resemblance to ALCL (reviewed in Refs 43 and 94). Clinical features are important in making the distinction between ALCL and LyP. Spontaneous regression being a constant feature of LyP, regression occurs infrequently in ALCL and is usually incomplete.
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ALCL as a clinical entity
Clinicopathological entity
The initial histopathological publications on the Ki-1 + LCL led directly to the definition of ALCL as a distinct clinicopathological entity. 4 Cytogenetic detection of the (2;5) translocation
The (2;5) translocation
Most NHL are karyotypically abnormal and the aberration patterns are reportedly more complex than in the leukemias. 108 Several primary abnormalities have been identified which correlate with distinct NHL entities, eg t(3;14)(q27;q32) in DLCL, t(8;14)(q24q32) in Burkitt's lymphoma, t(11;14)(q13;q32) in mantle cell lymphoma, and t(14;18)(q32;q21) in follicular lymphoma. 109 Cytogenetic work over the last 15 years has amply documented that a reciprocal translocation involving the short arm of chromosome 2 (band p23) and the long arm of chromosome 5 (band q35) is, although not specific for, highly associated with ALCL. The first description of this primary translocation was published in 1985, 5 albeit at the time it was identified as t(2;5)(p21;q35). This first and the following four cases were all described as malignant histiocytosis (which we now know is ALCL in most instances). 6 A literature review in 1988 showed that 10 out of 19 cases of malignant histiocytosis carried a breakpoint in 5q35, eight t(2;5)(p23;q35) and the two variants t(1;5)(p32;q35) and Table 4 Clinical spectrum of ALCL t(5;6)(q35;p12), concluding that a breakpoint in 5q35 could be specific for this disease (reviewed in Refs 110 and 111). Subsequently, the same rearrangement was then described in a number of cases, each of which were diagnosed as malignant histiocytosis. [112] [113] [114] The combined findings of four disciplines (pathology, cytogenetics, immunophenotyping and molecular biology, the latter for detection of T cell receptor rearrangements), have conclusively shown that the t(2;5)-carrying cells were not of histiocytic, but of lymphoid origin (reviewed in Ref. 115) . These studies established a strong link between the new cytogenetic abnormality t(2;5) and the new pathological entity ALCL.
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Incidence of t(2;5) in non-Hodgkin's lymphomas and Hodgkin's disease
The frequencies of the t(2;5) in NHL as detected by cytogenetic analysis have been reported in several large series and are in the range of 1-2% ( Table 5 ). The t(2;5) was not seen in more than 130 combined cases of HD in which cytogenetic analysis showed other clonal abnormalities. These series and the early case reports on malignant histiocytosis/ALCL suggested that the t(2;5) is a specific chromosomal marker for the entity. However, some studies found a number of t(2;5)
+ nonanaplastic NHL (mostly CD30 + ), including typical T cell NHL (peripheral T cell lymphoma, PCTL) and B cell NHL (DLCL and follicular). 37, 125, 127 Others contradicted this view, showing that, for instance, all PTCL with the t(2;5) were in fact cases of ALCL. 124, 135, 136 Whether this translocation is restricted to, and thus truly specific for, ALCL remains a somewhat seman- Leukemia tic discussion, but this is certainly also dependent on the correct diagnosis or the pathological definition of ALCL. In any event, the t(2;5) is definitely a recurring abnormality in ALCL (seen in 46% of the cases listed in Table 5 ).
Cytogenetic variants of the t(2;5)
The early publications on the association between the t(2;5) and malignant histiocytosis had already described several variant translocations; since then, others have expanded the spectrum of such cytogenetic variants in single cases (Table  6 ). Variants involving 2p23 were found in ALCL or rarely in other T cell or B cell NHL, and also in AML. A unique case of chronic eosinophilic leukemia with a t(2;5)(p23;q35) has been reported which, however, does not appear to have any relationship to ALCL. 138 Recently, two novel translocations, t(2;15)(p23;q22) and t(2;17)(p23;q21) in the setting of AML M1 and AML M4, respectively, were described. 151 However, neither the ALK gene nor the PML or RARA genes were disrupted. These latter two rearrangements together with other rearrangements affecting the 2p23 locus -t(2;3)(p23;q26), t(2;4)(p23;q25), t(2;4)(p23;q31), t(2;4)(p23;q35), del(2)(p23) -were all described in AML cases. [141] [142] [143] [146] [147] [148] [149] However, a chromosome band contains 10 to 15 megabases of DNA and thus many other genes might be affected. Variants involving 5q35, ie t(3;5)(q25.1;q34-35) and t(5;17)(q32or35;q12), have been detected in myelodysplastic syndromes (MDS) and AML. 155, 156, 161 Furthermore, masked or complex variants of the t(2;5) may exist which may not be detectable without additional analysis. For instance, cytogenetic analysis of the DEL cell line had shown a t(5;6)(q35;p21), whereas molecular analysis showed an NPM-ALK fusion (see below), suggesting a masked t(2;5;6). 165, 166 Cloning and (patho)physiology of genes involved in t(2;5) and variants
Cloning of the NPM-ALK genes involved in t(2;5)
Cytogenetic identification of the t(2;5) provided the stimulus for molecular studies of the genetic events that accompany this abnormality. Early studies identified several candidate genes: the proto-oncogene NMYC and FMS, the receptor for M-CSF (macrophage colony-stimulating factor) were localized on 2p24.3 and on 5q33.3, respectively; 111 while the two tyrosine kinase receptor genes FGFR4 (fibroblast growth factor receptor 4) and FLT4 (FMS-related tyrosine kinase 4) were both found on 5q35.3 and were translocated by the t(2;5)(p23;q35), t(3;5)(q25.1;q34), and t(5;6)(q35;p21) abnormalities, there was, however, no evidence for rearrangement or gene deregulation. 167, 168 Finally, the new recurrent t(5;11)(q35;p15.5), occurring in childhood AML with del(5q), produces a breakpoint between NPM and FLT4. 169 Using the t(2;5)-positive lymphoma cell lines SU-DHL-1 and SUP-M2, Morris et al 11 cloned the breakpoints of the t(2;5) and discovered that the translocation creates a fusion of the genes encoding NPM (for nucleophosmin, on 5q35) and the novel tyrosine kinase ALK (for anaplastic lymphoma kinase, on 2p23). Using the ALCL-derived cell line AMS3, the same ALK gene was cloned by a second group which termed the encoded protein p80. 137 The mechanism by which the (2;5) translocation occurs is not known. It may be that many illegitimate recombinations occur during normal cell division and are eliminated by DNA repair systems. For instance, for the t(15;17) fusion gene, it was reported that short stretches of identity between the PML and RARA genes were found in the breakpoint regions. Random cleavage of the genes was followed by attempts to repair of the breaks and joining of the loci; those clones containing the fusion transcript survived and had a growth advantage (reviewed in Ref. 170 ).
Physiology of ALK and NPM
The normal structure and function of human and mouse ALK has been analyzed by two groups. 171, 172 ALK is most closely related to the gene LTK (leukocyte tyrosine kinase) ( Table 7) . ALK is a large, glycosylated, single chain transmembrane receptor tyrosine kinase and a member of the insulin receptor family; the ligand of ALK is as yet unknown. ALK appears to play an important role in the normal development and function of the nervous system. 15, 171, 172 However, although other members of the receptor tyrosine kinase family are known to be involved in the regulation of cell growth and differentiation, 173 no definitive function has yet been ascribed to ALK. The absence of ALK protein in normal hematopoietic cells means that the expression of ALK in neoplastic cells can be regarded as a clonal tumor marker. 15, 174 NPM (also known as NPM1, B23, numatrin) is an RNAbinding nucleolar phosphoprotein which is ubiquitously expressed. Its cell cycle-dependent functions include the shuttling of ribonucleoproteins between the nucleolus and cytoplasm to the ribosomes.
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Pathophysiology of NPM-ALK
The t(2;5) leads to an in-frame fusion resulting in the expression of a functional fusion protein. With rare exceptions, an identical NPM-ALK mRNA fusion product was reported, indicating that the genomic rearrangement always involves the same introns of the two genes. 180 The aminoterminal 5Ј-end portion of NPM is joined to the entire cyto- Table 8 . plasmic catalytic domain of ALK on the derivative chromosome 5, der(5). 181 The reciprocal ALK-NPM chimeric transcript, which could have been generated from the der(2), does not appear to be generally expressed. 11 However, one study seems to have detected the reciprocal ALK-NPM by both DNA PCR and RT-PCR in a few cases and in the cell line SU-DHL-1. 182 In order to exclude PCR artifacts, these data need independent confirmation. The 80 kDa fusion protein NPM-ALK is a constitutively active tyrosine kinase [183] [184] [185] (Table 7) . NPM-ALK is localized within both the cytoplasmic and nuclear compartments of the cell. Heterodimers form between NPM-ALK and normal NPM which are translocated to the nucleus. This explains the nuclear and nucleolar distribution of NPM-ALK. However, the nucleus is not necessarily the site of action of this protein. 183, 185 It seems that malignant transformation by NPM-ALK does not involve the alteration of normal NPM functions, but absolutely requires the activated kinase function of ALK. 181, 183 The NPM portion of the NPM-ALK protein provides a dimerization domain for the activation of the ALK protein. 183 Transfection of NPM-ALK into the mouse/rat cell lines Ba/F3, NIH-3T3, Fr3T3 and Rat-1 led to a transformed phenotype of these cells in vitro. 137, 183, 184, 186 In vivo, human NPM-ALK expression in murine hematopoietic cells induced a transplantable B cell lymphoma. 187 With regard to signaling, phospholipase C-␥ (PLC-␥) appears to be an important downstream target of NPM-ALK. 184 Further studies showed that the adapter proteins SHC, GRB2, insulin receptor substrate 1 (IRS-1) and signal transducer and activator of transcription 5 (STAT 5) were tyrosine phosphorylated and bound to NPM-ALK in transformed cells, although the interaction with SHC and IRS-1 was found to be dispensable for transformation. 137, 188 Recent work has also detected constitutive activation of the signaling molecules phosphatidylinositol-3 kinase (PI-3K) and AKT kinase in NPM-ALK + Ba/F3 cells. 189 An interesting finding is the specific binding of NPM-ALK to the intracellular domain of the CD30 molecule which is mediated via the ALK portion of the chimeric protein. 12, 190 Although NPM-ALK does not seem to be stimulated by CD30 activation, 190 association with the CD30 receptor might extend the subcellular localization of NPM-ALK to membraneassociated proteins.
Leukemia
Taken together, it appears that results of the NPM-ALK gene fusion are: (1) the ectopic expression of ALK in lymphoid cells, driven by the strong NPM promoter; (2) the constitutive phospho-transferase activity with the NPM moiety serving as an activating sequence; and (3) signaling through various known molecules. 183, 191 
Pathophysiology of molecular variants
Screening efforts are ongoing to identify additional variant ALK gene fusions in ALCL. For example, cases ectopically expressing ALK protein only in the cytoplasm (and not in both the cytoplasm and the nucleus as in the classical NPM-ALK rearrangement) can be detected by simple immunostaining. 15 Approximately 15-20% of ALCL that express ALK do not contain the t(2;5), suggesting that there will be further candidate fusion partners for ALK. [16] [17] [18] Various groups cloned the breakpoints of the t(2;5) variants (Table 6) , and it was shown that several partners other than NPM can promote oncogenic expression of the ALK intracytoplasmic domain (Table 7) . A schematic representation of the various fusion genes encoded by parts of ALK and partner genes is shown in Figure 1 . Primers to detect these fusion genes are listed in Table 8 . The contribution of the various ALK partners during lymphoma- For abbreviations see legend to Table 1 .
genesis in vivo remains to be established. 24 There is preliminary evidence that cases of ALCL with one of the variant translocations have a good prognostic outlook; 192 however, more studies are necessary to ascertain whether such cases behave differently to cases with the classical t(2;5).
ATIC-ALK:
The inv(2)(p23q35) was found to fuse ALK and ATIC (for 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase) in all patients carrying the inversion. 22, 23 The fusion gene is detectable by RT-PCR (with identical fusion transcripts), the reciprocal (ALK-ATIC) fusion cDNA was not found. The amino terminus of ATIC, a bifunctional homodimeric enzyme that catalyzes the penultimate and final steps of de novo purine nucleotide biosynthesis, [193] [194] [195] fuses with the intracellular portion of the ALK receptor tyrosine kinase. The chimeric protein is localized in the cytoplasm and is constitutively tyrosine phosphorylated. 24 ATIC-ALK activation appears to be based on ATIC-mediated homo-dimerization. The fusion protein converted the cytokine-dependent Ba/F3 cell line to independent growth, caused neoplastic transformation of NIH-3T3 cells, formed stable complexes with the signaling proteins GRB2 and SHC, and induced tyrosine phosphorylation of SHC. 23, 24 The ATIC-ALK fusion appears to be the most common of the variant ALK fusion genes (Table 6 ). In a recent series, ATIC-ALK accounted for two of 15 (13%) cases positive for ALK by immunostaining or for NPM-ALK by RT-PCR. 22 
TFG-ALK:
The TFG (for TRK-fused gene) gene was identified as a new fusion partner for ALK in cases of ALCL, one of which exhibited a t(2;3)(p23;q21). 25 In these cases, two structurally different translocations created two TFG-ALK fusion genes, TFG-ALK S and TFG-ALK L . The TFG gene was initially detected as the rearranged partner of the NRTK1 gene, the same gene which is also the fusion partner of TPM3 in thyroid papillary carcinoma. The fusion of TFG with NTRK1 Leukemia forms the oncogene TRK-T3 that has transforming activity in various models. [196] [197] [198] The ALK breakpoint in these translocations was the same as in the classical t(2;5). Wild-type TFG is constitutively expressed in many different tissues. Both types of the TFG-ALK protein were localized in the cytoplasm and both had tyrosine kinase activity.
TPM3-ALK:
In an ALCL patient with the t(1;2)(q25;p23), the chromosomal rearrangement fused the ALK gene to sequences of the TPM3 gene which encodes non-muscular tropomyosin. 26, 199 Three further cases of ALCL were found to be positive for the TPM3-ALK transcripts, one of them due to a complex t(1;2) variant. 26, 140 The normally ubiquitously expressed TPM3 gene has been detected as a fusion partner with the TRK (also variously designated as TRKA or NTRK1) kinase gene in human papillary thyroid and colon carcinomas. [200] [201] [202] TPM3-ALK expression was restricted to the cytoplasm. It appears that the TPM3 gene contributes an active promoter for ALK expression. 26 The ALK intron involved was the same intron affected by the t(2;5).
Both TFG and TPM3 proteins contain dimerization motifs, and it is likely therefore that, as for NPM, these proteins permit dimers of TFG-ALK or TPM3-ALK to be formed. 25, 26 This dimerization process mimics ligand binding and results in the constitutive activation of the kinase domain.
Clues to the role of the NPM portion of the NPM-ALK fusion protein may also be derived from the investigation of two other recently described fusions involving NPM, namely NPM-MLF1 and NPM-RARA. The mechanistic analysis of these two fusions should indirectly further the understanding of NPM-ALK function. 203 
NPM-MLF1:
The t(3;5)(q25;q34-35) fuses NPM and MLF1 (for myelodysplasia-myeloid leukemia factor 1) in a uniform fusion junction.
157 MLF1 is normally located in the cytoplasm, whereas NPM-MLF1 is targeted to the nucleus, predominantly nucleolar. MLF1 transcripts were not detected in hematopoietic organs, suggesting that NPM-MLF1 contributes to the genesis of AML/MDS in part by enforcing the ectopic overexpression of MLF1. 204 The myeloid cell nuclear differentiation antigen (MNDA) is a nuclear protein expressed specifically in human myelomonocytic cells. It is of note, that MNDA binds the NPM-MLF1 protein which may thus contribute to the pathogenesis of myelomonocytic malignancies. 205 Curiously, NPM-MLF1 transfected into human K-562 cells was able to induce apoptosis, 206 while enforced expression of MLF1 in the murine J2E erythroleukemic cell line induced a lineage switch to a monoblastoid phenotype. 207 Recently, NPM-MLF1 was found to downregulate p27 KIP1 in K-562 cells. 208 The gene MLF2 which showed high homology to MLF1 is expressed ubiquitously and was mapped to chromosome 12p13; a preliminary screening failed to reveal MLF2 gene rearrangements. 209 
NPM-RARA:
The t(5;17)(q35;q12) fuses NPM and RARA (for retinoic acid receptor ␣). 162, 163 The NPM sequences contained in the shorter NPM-RARA cDNA are identical to the NPM sequences detected in the NPM-ALK fusion; the RARA sequences are the same as the RARA sequences seen in PML-RARA and PLZF-RARA, occurring in t(15;17) and t(11;17) acute promyelocytic leukemia (APL). 162 The NPM-RARA fusion gene is reviewed in detail in Ref. 170 . The leukemo-
Figure 2
Dilution experiments to test the sensitivity of the NPM-ALK RT-PCR assay. The left-hand side of the figure shows video print results from ethidium bromide-stained agarose gels; the right-hand side presents autoradiographic results obtained after Southern blotting and hybridization to specific 'internal' oligonucleotide probes. The results of PCRs for NPM-ALK are shown in the upper two panels; NPM-ALK/1 and NPM-ALK/2 refer to primer sequences as described by Morris et al 11 and Orscheschek et al, 14 respectively. The NPM-NPM and actin panels were performed to verify that the reactions contained equal amounts of starting material. The sensitivity of the NPM-ALK/1 primers was determined to be 1:10 3 in agarose gels and 1:10 5 for hybridization, that of NPM-ALK/2 was 1:10 4 in agarose gels and 1:10 6 for hybridization. JB-6 is an NPM-ALK + ALCL-derived cell line; MOLT-3 is an NPM-ALK − T acute lymphoblastic leukemia (T-ALL)-derived cell line. Dilutions indicated represent dilutions of JB-6 cells in MOLT-3 cells.
Figure 3
Autoradiography results from NPM-ALK RT-PCR of clinical patient material. The patient material was amplified by PCR using primers NPM-ALK/1 or NPM-ALK/2 which refer to primer sequences as described by Morris et al 11 and Orscheschek et al, 14 respectively. After Southern blotting, the amplicons were visualized by hybridization with radioactively labeled 'internal' oligonucleotide probes. The left-hand and right-hand sides of the figure display results after 2. genic role of NPM-RARA was established in transgenic mice. These transgenic mice developed a spectrum of phenotypes from typical APL to chronic myeloid leukemia (CML), but relatively late in life, suggesting that NPM-RARA is not sufficient for full-blown transformation. 210, 211 Cells carrying the NPM-
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Figure 4
Immunostaining for p80 protein in three lymphoma samples. Panel a shows staining of the t(2;5)
+ ALCL-derived cell line JB-6. Panel b depicts a case of t(2;5)
+ ALCL (Null-type, large cell). Panel c shows a case of HD (nodular sclerosis type II) with rare positive cells occurring at less than 1 in 1000 cells in focal areas (indicated by arrows); this was our only positive HD case among 82 HD cases studied. Modified APAAP immunostaining on paraffin sections; Mayer's Hemalaun counterstaining; in panels b and c the alternative substrate 2-bromo-3-chloro-4-indoyl-phosphate nitroblue tetrazolium was used producing a black staining; microphotographs were taken with × 63 (panel a) and × 40 (panels b and c) objectives.
RARA are responsive to differentiation-inducing treatment with all-trans retinoic acid. 210, 212 The NPM-RARA fusion protein interacts with co-repressor and co-activator proteins, exhibiting both positive and negative transcriptional properties.
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Methods for detection of t(2;5) NPM-ALK
Various detection methods
The ALCL-associated genetic abnormality can be demonstrated at the chromosome, DNA, RNA, or protein level, using various approaches (Table 9 ). Conventional karyotyping on Giemsa-banded metaphases is, of course, the traditional method for documenting the pathognomonic t(2;5). Falsenegative cases can be due to the analysis of non-malignant bystander cells in lieu of the neoplastic cells (which may not undergo mitosis), to the existence of cryptic aberrations, or to the difficult interpretation of poor-quality preparations. At the molecular cytogenetic level, fluorescence in situ hybridization (FISH) using specific fluorochrome-labeled probes permits detection of the NPM-ALK fusion in both metaphase and interphase cells. FISH has become a useful adjunct to classical cytogenetic demonstration of the genetic rearrangement. 215 An extension of the FISH technique is the combination of simultaneous immunophenotyping and interphase cytogenetics, termed FICTION (for fluorescence immunophenotyping and interphase cytogenetics as a tool for investigation of neoplasms). 217 NPM or ALK probes have been used in Southern blot detection of the NPM-ALK fusion. 11, 48, 218, 219 Although specific, Southern blotting is, however, laborious and time-consuming and the use of Southern blotting for routine diagnosis of the t(2;5) has been abandoned. Due to relatively short introns involved in the NPM-ALK fusion, this genomic rearrangement is amenable to detection by the so-called long-range, genomic DNA PCR. 203 Four studies have explored this molecular approach, confirming its reliability, rapidity and robustness. [219] [220] [221] [222] However, most workers prefered RT-PCR over genomic PCR.
The consistency of the NPM-ALK rearrangement provides the basis for the highly sensitive and specific gene fusion detection by RT-PCR. 203 RT-PCR is used either in its single step or nested version. Commonly, oligonucleotide primers specific for the NPM-ALK transcript and a primer pair derived from the ubiquitously expressed NPM gene as a control for reverse transcription and amplification are used, as described by Morris et al. 11 RT-PCR represented the first rapid, accurate and sensitive assay for detection of NPM-ALK. The NPM-ALK product can be specifically detected by hybridization with an end-labeled oligonucleotide homologous to sequences spanning the fusion junction (examples are shown in Figures 2 and 3 ). Isotopic RNA in situ hybridization (RISH) uses 35 S-labeled single-stranded RNA probes specific for ALK or NPM sequences. This method lends itself to the application on archival material and allows detection of gene products at the single cell level. 76 Finally, various antibodies were developed for demonstration of the NPM-ALK fusion at the protein level in both frozen and formalin-fixed paraffin-embedded material. First, a rabbit polyclonal anti-ALK antibody termed p80, which was widely used, and later the polyclonal antibody ALK11 were generated 13, 47, 226 (Figure 4) . Various McAbs were generated as well: (1) 224 ALK1 and ALKc were studied extensively and found to label only lymphomas, but no non-hematopoietic tumor specimens (over 200 were tested); no staining of any normal cells was seen apart from a few scattered cells in the central nervous system. 15, 17 The advent of anti-ALK McAbs was important for the detection of variant fusion partners for the ALK gene as these 15-20% of the ALCL cases are, of course, negative in the NPM-ALK PCR (see above). Hence, the histochemical detection of the cytoplasmic portion of ALK seems to be the most suitable method to ensure the involvement of ALK overall. In contrast to the anti-ALK McAbs, the polyclonal antibody p80 showed non-specific cross-reactivity with follicular dendritic reticulum cells, keratinocytes, smooth muscle in endothelium, dermal dendritic cells, epidermal adnexal cells, and fibroblast-like sinusoidal cells. 13, 15, 63, 223, 227 
Concordance between methods for t(2;5) NPM-ALK detection
In general, a good correlation was obtained in various comparisons in which the different detection methods for the t(2;5) NPM-ALK were directly compared with each other (Table 10) . Except for the following two studies, concordance rates were in the range of 70-100%: (1) while immunostaining and RT-PCR detected positivity for NPM-ALK in most ALCL cases found by cytogenetics to carry the t(2;5), classical cytogenetics failed to demonstrate the t(2;5) in all NPM-ALK + ALCL cases; in this study, application of FISH corrected the unsuccessful cytogenetic analysis; 60 (2) RT-PCR may encounter the difficulty of extracting high-quality RNA from paraffin-embedded tissue. 64 Use of nested RT-PCR may lead to the detection of false-positive cases: one study found 8% positivity after onestep RT-PCR which increased dramatically to 27% after the second RT-PCR. 182 There are, therefore, three basic approaches to detect the t(2;5) NPM-ALK: (1) cytogenetics (assisted by FISH); (2) PCR (commonly RT-PCR); and (3) immunostaining (commonly using McAbs). The present evidence suggests that the information provided by NPM-ALK RT-PCR and immunological detection of ALK expression is similar. From a practical point of view, ALK immunostaining, given its ease, rapidity, specificity, low-cost and additional information regarding cellular origin and histopathological context, appears to be the most useful technique. 228 RT-PCR which requires high-quality RNA and efficient amplification has greater sensitivity and may be applied for minimal residual disease follow-up. But one could also use ALK immunolabelling for minimal residual disease detection. The technique is sensitive enough and the rare positive cell could be easily detected in a biopsy. The advantages and disadvantages of the major detection methods are reviewed in Ref. 227 .
Occurrence of NPM-ALK in ALCL, Hodgkin's disease and other lymphomas
Incidence of NPM-ALK in ALCL
The use of the various detections methods (Southern blot, RNA in situ hybridization, DNA or RT-PCR, immunohistochemical staining) has enabled a broad survey of primary lymphoma tissues for evidence of the t(2;5) NPM-ALK to be performed. In ALCL, the reported frequency of NPM-ALK rearrangement has ranged from 7% to 100% (Table 11 ). The frequency of the NPM-ALK rearrangement among all 1084 reported ALCL patients is 43%, for children 86/103 (83%) and for adults 106/339 (31%) (as far as it has been possible to separate these age groups in the literature). The percentage of NPM-ALK positivity among ALCL cases is higher in some studies, probably because of stricter criteria for the diagnosis of ALCL, namely inclusion only of cases with a T or Null cell phenotype; exclusion of the 'B-ALCL cases' in those studies which detailed the immunophenotypes increases the incidence to 45% (458/1018). The differences in reported incidences among series may also reflect the proportion of HDlike ALCL and primary cutaneous ALCL studied (see below). In conclusion: (1) nearly half of all ALCL cases carry the t(2;5) NPM-ALK alteration; (2) the incidence is significantly higher in children compared to adults (83% vs 31%); and (3) neither anaplastic morphology nor the CD30 expression predict the presence of NPM-ALK.
Incidence of NPM-ALK in non-ALCL non-Hodgkin's lymphomas
An area of conflicting data concerns the non-ALCL NHL.
NPM-ALK has also been identified in non-ALCL NHL, in both CD30
+ and CD30 − NHL patients, including B cell and T cell NHL (Table 11 ). The diagnoses included mostly the nondescript term large cell lymphoma, but also diffuse large cell, diffuse mixed, and immunoblastic lymphoma. Overall, the incidence is 35/893 (4%), with about 1% for B-NHL and 1% for T-NHL (not all studies provided detailed data). It is important to emphasize that the distinction between some subtypes of LCL and ALCL may be difficult and obviously depends on the different interpretation of histomorphological features (institutional definition). Some cases may also have been diagnosed prior to the evolution of the current concept of ALCL. Taken together, these results do, however, demonstrate that NPM-ALK + non-ALCL cases of NHL are relatively rare.
Incidence of NPM-ALK in Hodgkin's disease
The NPM-ALK rearrangement was not detected in any of 645 HD cases in 22 series, but has been detected in seven series with frequencies ranging from 1% to 85% (Table 11 ). For abbreviations see legend to Table 1.   a The concordance rate for positive cases is indicated. b The concordance rate includes here congruent positive and congruent negative cases; the test method may detect NPM-ALK + ALCL cases which were not detected by the reference method (in the latter case, the concordance rate will decrease compared to the concordance rate seen for the positive cases).
Orscheschek et al 14 reported the highest incidence of 85%. This study has caused a large amount of controversy and spurred a plethora of studies disproving these findings (see below under 'Controversies'). These results remain unexplained; the fundamental question remains whether these data are caused by technical PCR artifacts or whether the cases reported to contain the t(2;5) are truly HD or instead represent morphologically similar ALCL variants. 181 But even with the inclusion of all studies, the overall frequency of the NPM-ALK rearrangement among all 867 screened cases of HD is only 3%, and is thus much lower than the frequency of 43% for all reported ALCL patients. In summary, the preponderance of evidence (including the fact that the translocation has never been observed in cytogenetic studies of HD) supports the notion that the t(2;5) NPM-ALK alteration does not play a significant role in HD.
Incidence of NPM-ALK in primary cutaneous ALCL and lymphomatoid papulosis
It is important to distinguish between primary cutaneous ALCL and primary nodal ALCL with secondary involvement of the skin since these diseases vary in response to treatment and clinical outcome. 94, [245] [246] [247] It has been suggested that LyP is a precursor lesion of primary cutaneous ALCL. The studies summarized in Table 12 indicate that the t(2;5) NPM-ALK is Leukemia absent in LyP (except for one study) and rare in most studies on primary cutaneous CD30 + ALCL. While the NPM-ALK aberration was not detected in six series totaling 36 patients, some groups found it to be present in 15 of 49 cases of primary cutaneous ALCL (however, only using either RT-PCR or immunostaining with the p80 antibody; none of these studies used the McAb ALK1). This produced an overall positive rate of just 15/85 (18%). This incidence compares to an overall positive rate of about 45% for primary nodal ALCL. It appears that the prevalence of 18% for primary cutaneous ALCL may be an overestimate: (1) as noted earlier, the p80 polyclonal antibody used in some studies has been shown to exhibit considerable cross-reactivity; and (2) detection of several positive cases required nested RT-PCR, being negative in the first-step RT-PCR. Secondary cutaneous ALCL resulting from large cell transformation of CTCL was also not associated with the t(2;5) NPM-ALK. 250 These data point to a molecular etiology of primary cutaneous ALCL and LyP distinct from that of nodal/systemic ALCL. 249 
Incidence of NPM-ALK in malignant hematopoietic cell lines
Investigators have been able to establish continuous cell lines from patients with the new entity ALCL. 115, 116, 118 A significant number of cell lines has been derived from tumors originally Table 14 ); primary cutaneous ALCL cases as far as indicated in the publication were not included (for details see Table 12 ). diagnosed as ALCL or as histiocytic lymphoma, malignant histiocytosis and other contemporary diagnoses used at the time (reviewed in Refs 251 and 252) ( Table 13 ). The ALCL cell lines SU-DHL-1 and SUP-M2 have been instrumental in the cloning of the NPM-ALK fusion gene. 11, 12 ALCL cell lines carrying the t(2;5) NPM-ALK are commonly used as positive controls in the detection of this genetic aberration; the most often used cell lines being JB6, Karpas-299, SU-DHL-1 and SUP-M2. 76, 218 In the analysis of more than 50 hematopoietic cell lines derived from various types of lymphoma, only ALCL cell lines were found to be positive for NPM-ALK by RT-PCR or ALK1 immunostaining ( Figure 5 ). It is of note that all HDderived and other CD30 + non-ALCL cell lines were negative. 15, 166 For abbreviations see legend to Table 1 . Table 14 gives an overview on the correlation of NPM-ALK with the major morphological variants of ALCL. While there may be some bias due to selected reporting, the overall positivity for NPM-ALK in all morphologically defined cases which are combined in Table 14 (204/408, 50%) corresponds approximately to the aggregate incidence of 43% for the disease entity ALCL in toto. The striking finding is the lack of positivity for NPM-ALK in the HD-like ALCL variant (5/87, 6%).
Correlation of NPM-ALK with morphological ALCL variants
Correlation of NPM-ALK with immunophenotype and patient age
With regard to the association of immunophenotype and ALCL, 44% and 45% of the T cell and Null cell ALCL cases displayed the t(2;5) NPM-ALK (Table 15 ). In contrast, only 8% of ALCL tumors with a B cell immunoprofile were positive. In Figure 5 RT-PCR analysis of HD-and ALCL-derived cell lines for expression of the NPM-ALK fusion transcript. Total RNA was extracted from the cell lines indicated, reverse transcribed and simultaneously analyzed for the chimeric NPM-ALK and the NPM cDNA. The expected PCR products of the NPM-ALK fusion transcript (177 bp) and of the not translocated normal NPM transcript (185 bp) were separated by electrophoresis and are shown in the upper panel. After transfer and sequential hybridization with either an NPM-ALK junction-specific (middle panel) or an NPM-specific oligonucleotide (NPM-NPM, lower panel), the nylon membranes were exposed to X-ray films. The NPM transcript was used as a control for amplifiable mRNA and the fidelity of the PCR reaction. Primers used were described by Morris et al. 11 The size marker is PBR322/HinfI. This figure is modified from our original figure shown in Ref. 166 as in the meantime the alleged cell line CO was found to be in reality the T-ALL cell line CCRF-CEM (here labeled as 'Control'). 253 The cell lines are described in detail in Refs 2, 251, 252. each of the 18 studies, the mean age of ALK-positive cases was significantly lower than the mean age of the ALK-negative cases: the average age of NPM-ALK + patients was found to be 8 to 31 years whereas NPM-ALK − patients were 30 to 68 years of age (Table 15) .
Correlation of NPM-ALK with prognosis
Two large studies on 1378 and 1841 patients showed that ALCL has a significantly better prognosis than all other types of non-ALCL NHL (parameters used were overall survival and The data refer to 3-year or mostly 5-year survival; the median follow-up and the details of treatment are different in the various studies and can be found in the respective references. b Only T cell and Null cell ALCL cases.
event-free survival). 33, 34 Six retrospective studies suggested that expression of NPM-ALK is associated with better overall prognosis (Table 16 ). However, three other studies could not find statistically significant differences in survival between positive and negative patients. It has been suggested that the better prognosis may have been due to younger age of the ALK + patients. A recent multivariate analysis showed that the survival advantage of ALK + ALCL patients was not merely secLeukemia ondary to their younger age. 47 An exact definition of the role of the t(2;5) NPM-ALK in the prognosis of ALCL will require prospective analysis of uniformly treated cohorts of patients (preferably of the same age group). With regard to primary cutaneous ALCL, one study came to the conclusion that NPM-ALK does not appear to be a prognostic factor. 248 An interesting finding is the recent evidence of an immune response to the ALK protein: autologous antibodies against For additional abbreviations see legend to Table 13 .
NPM-ALK could be detected in ALK + patients, but not in any of the control subjects. It was speculated that the presence of circulating anti-ALK antibodies may be relevant to the fact that ALK + ALCL has a relatively good prognosis. 255 A new promising approach to therapy is the inhibition of NPM-ALK expression by hammerhead ribozymes which were constructed to cleave the ALK portion of the NPM-ALK transcript. 
Non-specific PCR positivity for NPM-ALK?
The report that 11/13 HD cases examined by RT-PCR showed NPM-ALK fusion gene-specific bands generated a tremendous amount of controversy, resulting in a heated exchange of arguments 243, 257 and in a wealth of subsequent studies (none of which could ever confirm these data -see Table 11 ). A second area of controversy concerned the detection of NPM-ALK in primary cutaneous ALCL and LyP by one group, but not by most of the other investigators. 258 In both instances, it was generally believed that technical flaws in the performance and interpretation of the RT-PCR which is prone to false-positive results should be considered. Another, often forwarded explanation is the occurrence of fusion gene transcripts in apparently normal cells.
Fusion genes in normal cells
Evidence for fusion gene trancripts which are commonly associated with the malignant cells in leukemia and lymphoma have also been found in in healthy individuals. These fusion genes include AML1-ETO, BCL2-IGH, BCR-ABL, MLL-AF4, NPM-ALK and partial tandem duplications of the gene MLL (Table 17 ) (reviewed in Ref. 274 ). These fusion gene transcripts which initially were thought to represent operational clonal tumor markers have been detected by high sensitivity PCR. Sensitivity was enhanced by increased starting amounts of total RNA in the RT reaction, nested PCR, and increased numbers of amplification cycles, leading to an alleged sensitivity of as low as 1:10 7 to 1:10 8 . Peripheral blood, cord blood, bone marrow, and organ tissues have been screened. While most findings were confirmed in independent studies, the detection of MLL-AF4 in normal infant and fetal bone marrow and fetal liver was not substantiated by other groups which analyzed cord blood and fetal liver samples. 267, 268 In the present context is it of particular interest that one group detected NPM-ALK fusion transcripts in 14/29 (48%) peripheral blood samples from healthy individuals by RT-PCR, albeit in a very low proportion of peripheral blood cells. The positive cells were found in the CD19 + population (B cells) and in the CD14 + cells (monocytes). 272 However, two other groups could not confirm these findings: none of 10 and 16 peripheral blood samples from normal volunteers were positive for NPM-ALK in the DNA PCR and RT-PCR analysis, respectively. 271, 273 Furthermore, while four out of 10 tonsils demonstrated the presence of NPM-ALK transcripts, immunostaining with the McAb ALK1 was negative in all cases. 271 On balance, detection of NPM-ALK in normal tissues remains controversial; even if independently confirmed, its pathophysiological significance is unknown.
Fusion genes in Hodgkin's disease
The recent debate on the detection of the t(2;5) NPM-ALK in HD shows parallels to an identical diagnostic problem which kept hematopathologists busy some 5 years earlier. This controversy concerned the question of whether the chromosomal alteration t(14;18)(q32;q21), juxtaposing the BCL2 gene and the immunoglobulin heavy chain gene (IGH), 109 also occurs in H-RS cells as well as in follicular B cell lymphoma. [275] [276] [277] [278] [279] The apparent problem was also in the detection of BCL2-IGH by RT-PCR. Two groups found 27% and 32% of the HD cases to be positive for BCL2-IGH while the majority of studies could not confirm these data. Overall, only 73 of the 803 (9%) HD cases in 18 studies examined by RT-PCR were found to be positive for BCL2-IGH. [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] Furthermore, it was reported: (1) that in positive cases bystander cells, and not the H-RS cells, were positive; 293 (2) that BCL2-IGH was detected in 16/86 (19%) hyperplastic normal tissues such as reactive lymph nodes and tonsils; 282, 292, 296, 300, 301 and (3) that the cytogenetically detected t(14;18) was seen only rarely in HD.
129,302
B cell ALCL
ALCL with a B cell phenotype had been described in the original paper defining the entity ALCL and had been recognized by the Kiel classification. 4, 8 While the majority (81%) of ALCL cases displayed a T cell or Null cell immunophenotype, a significant percentage (17%) of morphologically defined CD30 + ALCL cases with a B cell immunoprofile have been reported (see Table 2 ). However, only a small percentage (8%) of these ALCL cases with a B cell phenotype were found to be ALK + , suggesting that 'true' B cell ALK + CD30 + cases do indeed exist, but are rather rare 47 (Table 15) . Thus, the REAL classification and the new WHO classification excludes B cell cases from the entity of ALCL and instead assigns these tumors to the category of diffuse large B cell lymphoma. 10, 19 Rare large B cell lymphoma with full-length ALK The absence of the ALK molecule from normal hematopoietic cells means that a positive immunostaining for ALK protein is essentially specific for the t(2;5) and variant translocations and is operationally pathognomonic for ALCL. The major exception is a rare large B cell lymphoma in which (by an unknown mechanism) a full-length ALK protein is expressed. 303 This rare novel high-grade NHL has been found in seven patients so far, most of them being male and adults. The disease followed an aggressive course. The cells were CD30
− and did not carry the classical t(2;5) nor any chimeric ALK fusion gene. 
ALK lymphoma
In 1998, Benharroch et al 16 proposed the new term 'ALK lymphoma', also described as 'ALKoma'. They described the morphological and immunophenotypical spectrum of 123 cases of lymphoma that all expressed the cytoplasmic portion of the ALK protein (after staining with the McAb ALK1), concluding that ALK + neoplasms represent a distinct entity. These findings were confirmed and extended by Falini et al. 17, 18 These cases encompassed most morphological ALCL variants. The tumor cells expressed epithelial membrane antigen, but lacked CD15, B cell markers, and EBV. 16 Clinically, in the largest series reported, ALK lymphomas mostly occurred in children and young adults (mean age of 22 years) with a male predominance and had significantly better overall survival than ALK − ALCL. 18 The entity ALK lymphoma includes cases with the classical NPM-ALK and ALK fusion variants. 192 In conclusion, it is clearly apparent that aberrant ALK expression is critical in the definition of ALCL as a disease entity and that the inclusion of this genetic marker as a diagnostic criterion further refines this heterogeneous category, a situation which may have prognostic implications. The definition of ALK lymphoma on the basis of the ALK protein expression has the great advantage that it is not subject to the problem of identication which would be caused by morphological review. Clearly, the use of McAbs to ALK has revolutionized the diagnosis of this particular tumor. The accurate identification of such tumors has implications for both treatment and the prognosis of patients.
